Shots: The NMPA has approved a P-I/II SWATCH dose-escalation & dose-expansion study that evaluates the safety, tolerability, and preliminary efficacy of selinexor in combination with the R2 regimen of lenalidomide […]readmore
Tags : IND
Shots: The NMPA has approved an IND application for P-Ib MATCH, dose-escalation study to evaluate the safety of ATG-008 + ATG-010 in patients with r/r DLBCL. The study will be […]readmore
Shots: The company will initiate the P-I/II dose-escalation & expansion study to evaluate the safety, PK & anti-tumor activities of IMP9064 as monothx. & in combination with Senaparib in patients […]readmore
Shots: The NMPA has approved the IND application of SPR206 (IV) for the treatment of MDR gram-negative bacterial infections. Everest will initiate the clinical program in China & results from […]readmore
Shots: Jounce to receive $85M upfront and $35M in its common stock under the terms of Sep 2020 agreement. Additionally, it is eligible to receive upto $660M in future clinical, […]readmore
Shots: The US FDA has approved the IND application of oral Asieris’ APL-1202 + BeiGene’s tislelizumab as neoadjuvant therapy in patients with MIBC The P-I/II study will evaluate the safety […]readmore
Shots: The NMPA has approved the IND application for the P- III SIENDO trial to evaluate the safety and efficacy of selinexor for advanced or recurrent endometrial cancer. The trial […]readmore
Shots: The US FDA has approved the IND application of HLX04-O for the treatment of wAMD The P-III clinical study of HLX04-O will be conducted to further evaluate the efficacy […]readmore
Shots: Henlius reported that NMPA has approved the IND application of HLX15 for the treatment of multiple myeloma The company has compared HLX15 in a head to head study with […]readmore
Shots: Sorrento has filed an IND for STI-1499 in patients hospitalized with COVID-19. In preclinical studies, STI-1499 has demonstrated 100% neutralizing effect (in vitro) against the highly contagious D614G mutant […]readmore